surgical medicalNew
Johnson & Johnson Ottava
Next-gen soft-tissue robotic surgery system
weight 0.0Flux 62▴PaidLaunched 2026-06
💸 No earnings reported yet
What it is
J&J MedTech's Ottava robotic surgical system for complex general and soft-tissue surgery, submitted to the FDA for De Novo authorization in 2026.
How AI plugs in
Integrates with J&J's connected digital-surgery ecosystem for data-driven procedure analytics and instrument intelligence.
★ Reviews
No reviews yet — be the first.Your rating